Futures firm with focus on Fed, earnings rush By Reuters

© Reuters. A nearly empty trading floor is seen as preparations are made for the return to trading at the NYSE in New York

By Medha Singh and Devik Jain

(Reuters) – U.S. stock futures rose on Monday after a two-day slide for Wall Street, as bets on a more dovish outlook from the U.S. Federal Reserve brightened the mood ahead of a busy week for quarterly earnings reports from companies including Boeing and Apple.

The S&P 500 and Dow logged their first weekly decline in four on Friday, following concerns over escalating coronavirus cases in southern and western U.S. states, rising tensions between the U.S. and China, and data that showed a recovery in the U.S. job market unexpectedly stalled.

Trillions of dollars in fiscal and monetary stimulus have been pivotal in bringing the S&P 500 to within 5% of its record high in hit February.

While no major announcements are expected at the end of the U.S. central bank’s two-day meeting on Wednesday, analysts expect policymakers to lay the groundwork for more action in September or in the fourth quarter.

Investors are also keeping a close watch on progress over the next round of government aid with less than a week before enhanced unemployment benefits expire.

Top aides to President Donald Trump said they agreed in principle with Senate Republicans on a $1 trillion coronavirus relief package, which will now be negotiated with Democrats.

Earnings reports will also be a major focus this week with 189 companies from the S&P 500 companies expected to report results, including Boeing Co (N:), Pfizer Inc (N:), Facebook Inc (O:), Apple Inc (O:), Amazon.com Inc (O:) and Alphabet Inc (O:).

At 6:15 a.m. ET, were up 109 points, or 0.41%, S&P 500 e-minis were up 14.75 points, or 0.46% and were up 81.5 points, or 0.78%.

Investors will get the first glimpse of the second-quarter U.S. GDP report on Thursday, which is likely to show the economy contracted by 34% in the three-month period.

Moderna Inc (O:) rose 6.9% premarket after the drugmaker said it had received an additional $472 million from the U.S. government’s Biomedical Advanced Research and Development Authority (BARDA) to support development of its novel coronavirus vaccine.

 

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.

Be the first to comment

Leave a Reply

Your email address will not be published.


*